Clinical efficacy comparison of HA280 and DNA280 immunoadsorption column in treating systemic lupus erythematosus

References

• Wener MH. Immune complexes in systemic lupus erythematosus. In: Tsokos GC, Gordon C, Smolen JS (eds), Systemic lupus erythematosus, 1st edn. Philadelphia: Mosby; 2007. pp. 214–24.
   Google Scholar
• American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50(11):3418–26.
   PubMed Web of Science ®Google Scholar
• Wallace DJ. Severe lupus. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds), Rheumatology, 3rd edn. Edinburgh: Mosby; 2003. pp. 1419–25.
   Google Scholar
• Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135(4):248–57.
   PubMed Web of Science ®Google Scholar
• Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus. 2004;13(5):366–71.
   PubMed Web of Science ®Google Scholar
• Stummvoll GH, Julius U, Derfler K, Aringer M. Immunoadsorption for systemic lupus erythematosus. Atheroscler Suppl. 2009;10(5):110–3.
   PubMed Web of Science ®Google Scholar
• Hohenstein B, Bornstein SR, Aringer M. Immunoadsorption for connective tissue disease. Atheroscler Suppl. 2013;14(1):185–9.
   PubMed Web of Science ®Google Scholar
• Hershko AY, Scheiman-Elazari A, Aamar S, Naparstek Y. Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study. Immunol Res. 2013;56(2-3):376–81.
   PubMed Web of Science ®Google Scholar
• Stummvoll GH, Schmaldienst S, Smolen JS, Derfler K, Biesenbach P. Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity. Nephrol Dial Transplant. 2012;27(2):618–26.
   PubMed Web of Science ®Google Scholar
• Stummvoll GH. Immunoadsorption (IAS) for systemic lupus erythematosus. Lupus. 2011;20(2):115–9.
   PubMed Web of Science ®Google Scholar
• Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jiménez-Boj E, Hörl WH, et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis. 2005;64(7):1015–21.
   PubMed Web of Science ®Google Scholar
• Stummvoll GH, Aringer M, Jansen M, Smolen JS, Derfler K, Graninger WB. Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. Wien Klin Wochenschr. 2004;116(21–22):716–24.
   PubMed Web of Science ®Google Scholar
• Biesenbach P, Schmaldienst S, Smolen JS, Hörl WH, Derfler K, Stummvoll GH. Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity. Atherosclerosis Suppl. 2009;10(5): 114–21.
   PubMed Web of Science ®Google Scholar
• Braun N, Erley C, Klein R, Kötter I, Saal J, Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant. 2000;15(9):1367–72.
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Vivenzio A, Di Giacomo S, Mareri M, Ceccarelli F, Valesini G. Cyclophosphamide and immunoadsorption apheresis treatment of lupus nephritis nonresponsive to drug therapy alone. BioDrugs. 2005;19(2):129–33.
   PubMed Web of Science ®Google Scholar
• Suzuki K. The role of immunoadsorption using dextran-sulfate cellulose columns in the treatment of systemic lupus erythematosus. Ther Apher. 2000;4(3):239–43.
   PubMedGoogle Scholar
• Sugimoto K, Yamaji K, Yang KS, Kanai Y, Tsuda H, Hashimoto H. Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis. Ther Apher Dial. 2006;10(2):187–92.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDA I: a disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630–40.
   PubMed Web of Science ®Google Scholar
• Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3(6):423–53.
   PubMed Web of Science ®Google Scholar
• Ren LM, Ye H, Zhao JX, Pan SS, Su ZG. 5-year survival rate and prognostic factor analysis of systemic lupus erythematosus. Chinese J Rheumatol. 2009;13(3):156–8.
   Google Scholar
• Terman DS, Buffaloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, Ayus JC. Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet. 1979; 2(8147):824–7.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Yu YT, Zhang HW, Guo DM, Li ZF. The clinical effect observation of DNA immunoadsorption therapy of systemic lupus erythematosus with double-stranded DNA antibody positive. Chinese General Practice. 2010;13(7c):2332–4.
   Google Scholar
• Shuzhen Z, Guangzhen L, Shirong W. The clinical observation of DNA immunoadsorption therapy on lupus nephritis. Chinese J Blood Purif. 2009;8(10):541–4.
   Google Scholar
• Kong WH, Ye ZZ, Li B, He WZ, Chen YS, Xie Y, et al. The clinical comparative study for the immunoadsorption therapy of severe systemic lupus erythematosus. J Pract Med. 2011;27(20):3721–3.
   Google Scholar
• Han ZW, Yao GQ, Li J, Xiao Q, Wang Q, Xu YP. Different immunoadsorption method contrast research for the treatment of systemic lupus erythematosus. Chinese J Blood Purif. 2010;9(7):380–4.
   Google Scholar
• Graninger M, Schmaldienst S, Derfler K, Graninger WB. Immunoadsorption therapy (therasorb) in patientswith severe lupus erythematosus. Acta Med Austriaca. 2002;29(1):26–9.
   PubMedGoogle Scholar
• Peutz-Kootstra CJ, de Heer E, Hoedemaeker PJ, Abrass CK, Bruijn JA. Lupus nephritis: lessons from experimental anireal models. J Lab Clin Med. 2001;137(4):244–60.
   PubMed Web of Science ®Google Scholar
• Conti G, Coppo R, Amore A.Pathogenesis of systemic lupus erythematosus (LES). G Ital Nefrol. 2012;29 Suppl 54:S84–90.
   PubMedGoogle Scholar
• Miyake K, Sasatomi Y, Nakashima H. Lupus nephritis associated with nephritic syndrome. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(3):129–33.
   PubMedGoogle Scholar
• Miyake K, Akahoshi M, Nakashima H. Th subset balance in lupus nephritis. J Biomed Biotechnol. 2011;2011:980286.
   PubMed Web of Science ®Google Scholar
• Levy J, Degan N. Correcting immune imbalance: the use of Prosorba column treatment for immune disorders. Ther Apher Dial. 2003;7(2):197–205.
   PubMed Web of Science ®Google Scholar